Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drugs. 2013 May;73(6):517-32. doi: 10.1007/s40265-013-0032-4.

Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents.

Author information

  • 1Division of Medical Oncology, Department of Medicine, University of Colorado, Mail Stop 8117, 12801 E. 17th Avenue, Room 8105, Aurora, CO 80045, USA. Eamon.Berge@ucdenver.edu

Abstract

Metastatic non-small cell lung cancer remains a disease with a high annual incidence and annual mortality worldwide, with limitations in first-line treatment past a fixed amount of platinum doublet chemotherapy for patients that do not harbor a targetable genetic abnormality such as an EGFR mutation or ALK gene rearrangement. Previous attempts to extend first-line treatment past 4-6 cycles of conventional cytotoxic chemotherapy have been disappointing, resulting in diminished quality of life and increased toxicity without improvement of progression-free or overall survival. Several advances in third-generation chemotherapy and targeted agents have generated a renewed interest in maintenance therapy, with several randomized phase III trials reporting a significant improvement in progression-free and overall survival with manageable toxicity profiles. The availability of new chemotherapy agents, tyrosine kinase inhibitors, and immunotherapy agents with a more tolerable or nonoverlapping toxicity profile have resulted in improvements in progression-free survival and median overall survival in maintenance settings with specific agents such as pemetrexed and erlotinib. Patients who are responding to first-line therapy, have not suffered a detrimental decrease in quality of life or performance status, and understand the risks and benefits of further immediate chemotherapy should be considered for maintenance treatment.

PMID:
23591906
[PubMed - indexed for MEDLINE]
PMCID:
PMC4162404
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk